Full-Time
Confirmed live in the last 24 hours
Develops drugs for muscle function disorders
$365k - $403kAnnually
Expert
San Bruno, CA, USA
You match the following Cytokinetics's candidate preferences
Employers are more likely to interview you if you match these preferences:
Cytokinetics focuses on developing medicines that improve muscle function for patients with cardiovascular and neuromuscular diseases. Their products are small molecule drugs designed to either enhance or inhibit muscle function, tailored to specific therapeutic needs. The company has a pipeline of drugs, including omecamtiv mecarbil and reldesemtiv, which are in various stages of clinical trials. Unlike many competitors, Cytokinetics emphasizes rigorous scientific research and has conducted over 50 clinical trials to ensure the effectiveness of its treatments. The goal is to bring new therapies to market that address the unmet needs of patients suffering from conditions like heart failure, ALS, and HCM.
Company Size
501-1,000
Company Stage
IPO
Total Funding
$58.4M
Headquarters
South San Francisco, California
Founded
1998
Help us improve and share your feedback! Did you find this helpful?
SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) - Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 9:00 AM Pacific Time in the Borgia Room of the Westin St. Francis Hotel in San Francisco, CA.
Cytokinetics announces Sanofi acquired rights to develop and commercialize Aficamten in Greater China.
Intech Investment Management LLC invests $1.73 million in Cytokinetics, Incorporated (NASDAQ:CYTK).
Setting the stage for its first consumer product after 25 years as a biopharma development company, Cytokinetics has launched "HCM Beyond the Heart," an awareness campaign educating cardiologists and other healthcare professionals (HCP) about the personal burdens caused by hypertrophic cardiomyopathy (HCM), a leading cause of sudden cardiac death.
Armistice Capital has invested in Cytokinetics Incorporated, a late-stage biopharmaceutical organization investigating treatments for impaired muscle function-related cardiovascular and neuromuscular diseases.